• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

LT-106-175

(CAS: 1429515-49-0 )

Suppliers of LT-106-175

Company Name Email Tel Country
AMEDCHEM s[email protected] +862168061059 CHINA

Fax: Purity: Brand:

Inquiry Online

Salutation: *Country:
*Customer: *Company Name:
*Email: *Request quantity:
Remarks:
 

Notice: Your contact information will be sent to selected suppliers.

* Required Fields.

Background Information of LT-106-175

LT-106-175, a multiple kinases inhibitor, shows potent inhibitory activities against CDKs and FLT3 with IC50s of 0.60±0.11 nM, 3.33±0.25 nM, and 9.10±0.16 nM for FLT3, CDK6, and CDK2, respectively. Fms-like tyrosine kinase 3 (FLT3) is among the most frequently mutated protein in acute myeloid leukemia (AML), which has been confirmed as an important drug target for AML chemotherapy.

Solubility of LT-106-175

Solubility Sources

Storage Condition of LT-106-175

Storage Condition Sources

MSDS Information

MSDS Sources

Quality Control and Spectral Data

QC Reports Sources

Mechanism and Indications

Signaling Pathways Protein Tyrosine Kinase/RTK Cell Cycle/DNA Damage
Target CDK FLT3
Research Area Cancer
Indications

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase

Chemical Information

M.Wt Formula CAS No. Synonyms
448.54 C22H24N8OS 1429515-49-0

Structure Information of LT-106-175

Smiles N1(C)CCN(CC2C=CC(NC(=O)C3=NNC=C3NC3N=CN=C4SC=CC=34)=CC=2)CC1
InChI InChI=1S/C22H24N8OS/c1-29-7-9-30(10-8-29)13-15-2-4-16(5-3-15)26-21(31)19-18(12-25-28-19)27-20-17-6-11-32-22(17)24-14-23-20/h2-6,11-12,14H,7-10,13H2,1H3,(H,25,28)(H,26,31)(H,23,24,27)

Related Products

Other Form Products of LT-106-175

Name CAS Formula Suppliers

Recommended Products in Same Target

Name CAS Formula Suppliers
LY2857785 1619903-54-6 C26H36N6O 12
THZ2 1604810-84-5 C31H28ClN7O2 10
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 22
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 5
ML167 1285702-20-6 C19H17N3O3 15
AMG 925 1401033-86-0 C26H29N7O2 15
LDC000067 1073485-20-7 C18H18N4O3S 11
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 8
LEE011 (succinate) 1374639-75-4 C27H36N8O5 9
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 8
LEE011 1211441-98-3 C23H30N8O 21
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 6
Wogonin 632-85-9 C16H12O5 28
1-NM-PP1 221244-14-0 C20H21N5 17
WHI-P180 211555-08-7 C16H15N3O3 13
THZ1 1604810-83-4 C31H28ClN7O2 18
Senexin A 1366002-50-7 C17H14N4 8
CDK4-IN-1 1256963-02-6 C22H29ClN8 9
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 16
Purvalanol B 212844-54-7 C20H25ClN6O3 22

Recommended Products in the Same Indication

Name CAS Formula Suppliers

Chemical and Physical Properties

Appearance: Melting point:
Boiling point: Flash Point:
Water Solubility: Solubility:
Density: Merck:
BRN: Refractive Index:
Vapour: EINECS:
Optical Rotation: alpha:

Reference

[1].Zhi Y, et al. Discovery of the selective and efficacious inhibitors of FLT3 mutations. Eur J Med Chem. 2018 Jun 5;155:303-315.
Fms-like tyrosine kinase 3 (FLT3) is among the most frequently mutated protein in acute myeloid leukemia (AML), which has been confirmed as an important drug target for AML chemotherapy. Starting from the lead compound LT-106-175, a series of 1-H-pyrazole-3-carboxamide derivatives were synthesized to improve the FLT3 inhibitory potency and selectivity. Among them, compound 50 was identified as a highly potent and selective FLT3 inhibitor (IC50 = 0.213 nM), which showed equal activities against various mutants of FLT3 including FLT3 (ITD)-D835V and FLT3 (ITD)-F691L that is resistant to quizartinib. Compound 50 also exhibited efficacy against the human AML cell line MV4-11 (IC50 = 16.1 nM) harboring FLT3-ITD mutants. Inversely, compound 50 displayed no cytotoxicity to FLT3-independent cells, and the biochemical analyses showed that its effects were related to the inhibition of FLT3 signal pathways. Additionally, compound 50 induced apoptosis in MV4-11 cell as demonstrated by flow cytometry. Moreover, compound 50 showed enhanced metabolic stability. Altogether, it was concluded that compound 50 could be a promising FLT3 inhibitor for further developing therapeutic remedy of AML.

Tags: buy LT-106-175 | LT-106-175 IC50 | LT-106-175 price | LT-106-175 cost | LT-106-175 solubility | LT-106-175 purchase | LT-106-175 manufacturer | LT-106-175 research buy | LT-106-175 order | LT-106-175 MSDS | LT-106-175 chemical structure | LT-106-175 Storage condition | LT-106-175 molecular weight | LT-106-175 mw | LT-106-175 datasheet | LT-106-175 supplier | LT-106-175 cell line | LT-106-175 NMR | LT-106-175 MS | LT-106-175 IR | LT-106-175 solubility | LT-106-175 Safe information | LT-106-175 Qc and Spectral Information | LT-106-175 Clinical Information | LT-106-175 Clinical Trial | LT-106-175 Route of Synthesis | LT-106-175 storage condition | LT-106-175 diseases and conditions | LT-106-175 flash point | LT-106-175 boiling point | LT-106-175 melting point | LT-106-175 storage condition | LT-106-175 brand